Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PTCT 
PTC Therapeutics Inc (PTCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PTCT (1-star) is a SELL. SELL since 2 days. Profits (3.20%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -11.78% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.68B USD | Price to earnings Ratio - | 1Y Target Price 64.71 |
Price to earnings Ratio - | 1Y Target Price 64.71 | ||
Volume (30-day avg) 919834 | Beta 0.66 | 52 Weeks Range 24.00 - 58.38 | Updated Date 04/1/2025 |
52 Weeks Range 24.00 - 58.38 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -45.03% | Operating Margin (TTM) -7.45% |
Management Effectiveness
Return on Assets (TTM) -5.09% | Return on Equity (TTM) -7740.12% |
Valuation
Trailing PE - | Forward PE 19.05 | Enterprise Value 5348981605 | Price to Sales(TTM) 4.56 |
Enterprise Value 5348981605 | Price to Sales(TTM) 4.56 | ||
Enterprise Value to Revenue 6.63 | Enterprise Value to EBITDA -10.22 | Shares Outstanding 78869400 | Shares Floating 63209855 |
Shares Outstanding 78869400 | Shares Floating 63209855 | ||
Percent Insiders 2.45 | Percent Institutions 99.94 |
Analyst Ratings
Rating 3.73 | Target Price 58.36 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold 3 | Sell 2 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
PTC Therapeutics Inc
Company Overview
History and Background
PTC Therapeutics, Inc. was founded in 1998. It is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule drugs targeting post-transcriptional control processes.
Core Business Areas
- Rare Diseases: Focuses on the discovery, development and commercialization of treatments for rare genetic disorders.
Leadership and Structure
The leadership team is headed by CEO Matthew B. Klein. The organizational structure includes research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Translarna (ataluren): A drug for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation. Competitors include Sarepta Therapeutics' Exondys 51 and Amondys 45.
- Emflaza (deflazacort): A corticosteroid used to treat Duchenne muscular dystrophy (DMD). Competitors include generic corticosteroids and other DMD-specific therapies.
- Evrysdi (risdiplam): Collaboration with Roche and Genentech. Treats spinal muscular atrophy. Competitors include Zolgensma (Novartis) and Spinraza (Biogen). PTC receives royalties.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the rare disease space, is characterized by high research and development costs, regulatory hurdles, and market exclusivity. The industry is experiencing growth due to increasing awareness of rare diseases and advancements in genetic therapies.
Positioning
PTC Therapeutics is positioned as a company specializing in rare disease therapies. Its competitive advantages include its focus on post-transcriptional control processes and its established portfolio of approved drugs.
Total Addressable Market (TAM)
The total addressable market for rare disease therapeutics is estimated to be hundreds of billions of dollars. PTC Therapeutics is positioned to capture a portion of this market with its existing portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Established rare disease portfolio
- Focus on innovative drug targets
- Collaborations with major pharmaceutical companies
- Experienced management team
Weaknesses
- High reliance on a few key products
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
- Ongoing clinical trials expose risk if trials fail.
Opportunities
- Expanding the pipeline with new drug candidates
- Acquiring or partnering with other rare disease companies
- Geographic expansion into new markets
- Increased awareness and diagnosis of rare diseases
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new therapies
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- SRPT
- BIIB
- NVS
Competitive Landscape
PTC Therapeutics competes with other pharmaceutical and biotechnology companies in the rare disease space. Its advantages include its focus on specific genetic disorders and its established portfolio of approved drugs. Disadvantages may include its smaller size and resources compared to larger competitors.
Major Acquisitions
BioElectron Technology Corporation
- Year: 2022
- Acquisition Price (USD millions): 225
- Strategic Rationale: Expanded PTC's pipeline with a preclinical program targeting mitochondrial diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would need to be assessed based on PTC Therapeutics' financial reports.
Future Projections: Future growth projections are available from analyst reports and company guidance.
Recent Initiatives: Recent strategic initiatives include expanding the pipeline with new drug candidates and seeking regulatory approvals for existing products in new markets.
Summary
PTC Therapeutics is a biopharmaceutical company focusing on rare diseases, demonstrating strength in its established portfolio and innovative drug targets. However, it faces challenges, including reliance on key products and competitive pressures. Continued success depends on pipeline expansion and navigating regulatory hurdles. Management needs to balance opportunity with threats.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
SRPT
Sarepta Therapeutics Inc
SRPT
Sarepta Therapeutics Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- PTC Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PTC Therapeutics Inc
Exchange NASDAQ | Headquaters Warren, NJ, United States | ||
IPO Launch date 2013-06-20 | CEO & Director Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 939 | Website https://www.ptcbio.com |
Full time employees 939 | Website https://www.ptcbio.com | ||
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.